Evidence map›Paper›PMID 25869077›Full record

ArticleLeukemia research2015

Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.

Vu H Duong, Maria R Baer, Franklin Hendrick, Sheila R Weiss, Masayo Sato, Amer M Zeidan, Steven D Gore, Amy J Davidoff

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022
    Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vu H DuongUniversity of Maryland Marlene and Stewart Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: vduong@umm.edu.
Maria R BaerUniversity of Maryland Marlene and Stewart Greenebaum Cancer Center and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Franklin HendrickPharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Sheila R WeissPharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Masayo SatoPharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Amer M ZeidanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Steven D GoreSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Amy J DavidoffAgency for Healthcare Research and Quality, Rockville, MD, USA.

Funding

Targeting Epigenomics in Myeloid NeoplasmsK24CA111717 · NCI · YALE UNIVERSITY · PI GORE, STEVEN D · 2005 to 2015
$1.7M
Comparative Effectiveness: Erythropoietic Stimulating Agents in Treatment of MDSRC1CA145831 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI DAVIDOFF, AMY J · 2009 to 2010
$774k
NCI NIH HHS K24 CA111717NCI NIH HHS RC1 CA145831NCI NIH HHS RC1 CA145831-01
6 · The paper itself

Abstract

introductionErythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with myelodysplastic syndrome (MDS) in clinical trials. We studied the association of timing of ESA initiation, agent (epoetin alfa, darbepoetin) and number of weeks of ESA use with response in MDS patients in routine practice.

methodsPatients diagnosed with MDS from 2001 to 2005 were identified in the Surveillance Epidemiology and End Results-Medicare linked database. The study cohort consisted of patients with new-onset transfusion dependence (TD). All patients received an ESA at least once during the study period, which began the week that criteria for TD were met and continued until transfusion independence (TI). Kaplan-Meier statistics and Cox Proportional Hazard models were used to assess relationships between time to ESA initiation, agent and number of weeks of ESA use and TI attainment.

resultsOf 610 TD patients treated with ESAs, 210 (34.4%) achieved TI. Median time from ESA initiation to TI was 13 weeks. Shorter time from TD to ESA initiation and use of darbepoetin were associated with higher probability of achieving TI. The probability of achieving TI decreased beyond 8 weeks of treatment, and was very low beyond 16 weeks (8-15 weeks: HR=0.64, 16-31 weeks: HR=0.25, 32+ weeks HR=0.10).

conclusionsIn this observational, population-based study, variations in ESA administration impacted response in transfusion-dependent MDS patients, with higher response rates with early administration and use of darbepoetin, and low response likelihood in non-responders beyond 16 weeks of therapy.

Indexed as

Blood TransfusionAgedAged, 80 and overDarbepoetin alfaDatabases, FactualEpoetin AlfaErythropoietinHematinicsHumansMaleMiddle AgedMyelodysplastic SyndromesRecombinant ProteinsRetrospective StudiesDarbepoetin alfaEpoetin AlfaErythropoietinHematinicsRecombinant ProteinsAnemiaComparative effectivenessErythropoiesis-stimulating agentsMyelodysplastic syndromes

Identifiers

PMID25869077
PMCPMC4441842

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.